MicroPort CRM, a pioneering company in the field of Cardiac Rhythm Management, headquartered in France, has recently received the pharmaceuticals and medical devices agency (PMDA) Japanese regulation agency approval for the latest range of implantable pacemakers, named Alizea. The devices are equipped with bluetooth technology for streamlined remote monitoring when paired with MicroPort CRM’s SmartView Connect home monitor, already approved in Japan.
Alizea pacemakers allow cardiologists to monitor devices remotely. The SmartView Connect home monitor is designed to be placed at the patient’s bedside to enable the regular transmission of detailed reports to the cardiologist on the functioning of the pacing system, removing the need for patients to visit the hospital for simple routine examinations, and thus reducing the burden on the healthcare system. Alizea pacemakers and the SmartView Connect home monitor work together to provide the cardiologist with timely alerts and transmissions triggered by patients when they present symptoms, leading to faster and more efficient patient care.
Benoît Clinchamps, president of MicroPort CRM (Paris, France), noted, “We successfully launched Alizea in Europe in June 2021, and Japan is the second region to benefit from its advanced technological functions. As part of our commitment to improve the lives of as many patients as possible, and to support healthcare professionals in their mission, we will continue to deploy Alizea and Smartview Connect around the world.”
Are you Hiring?
